Virulence Factor, cagA Test

Roughly half the world's population carries Helicobacter pylori, the spiral bacteria that quietly lives in the stomach. Most carriers never develop ulcers or stomach cancer. The single biggest factor separating those who do from those who don't is whether the strain they carry has cagA (cytotoxin-associated gene A), a gene that roughly doubles stomach cancer risk and sharply raises ulcer risk.

This stool test looks for the cagA gene in the H. pylori living in your gut. If you already know you are infected, the answer moves the conversation from "do I have an infection?" to "how aggressively should I treat it?"

What This Test Actually Detects

The cagA gene sits inside a cluster of bacterial DNA called the cag pathogenicity island. When this cluster is intact, the bacteria builds a tiny molecular needle (called a type IV secretion system) that injects the CagA protein directly into the cells lining your stomach. Once inside, CagA scrambles normal cell signaling, drives chronic inflammation, and pushes cells toward changes that can eventually become cancer.

About 60 to 70 percent of H. pylori strains in Western countries carry cagA, and the share is often higher in East Asia, parts of Africa, and among populations with heavier H. pylori burdens. Strains carrying an East Asian version of the gene tend to provoke even stronger inflammation than the Western version.

Stomach Cancer Risk

The link between cagA-positive H. pylori and stomach cancer is one of the most consistent findings in gastrointestinal research. A meta-analysis of human studies found that infection with a cagA-positive strain raises stomach cancer risk by 1.64 times compared with infection by a strain that lacks the gene.

A large German cohort that followed nearly 10,000 adults reported an even larger gap when comparing cagA-positive carriers to uninfected people. People infected with a cagA-positive strain had roughly an 18-fold higher risk of noncardia gastric cancer (the main type of stomach cancer), while people infected without the cagA gene had about a 5-fold higher risk than uninfected adults.

Source: ESTHER cohort (Holleczek 2020), Huang et al. 2003 meta-analysis, Gwack et al. 2006 nested case-control.

What this means for you: a cagA-positive result is not a diagnosis of cancer, but it is a clear signal that the strain you carry belongs to the higher-risk category and should be eradicated rather than left alone. The risk climbs further if your infection has already produced atrophic gastritis (thinning of the stomach lining) or intestinal metaplasia (a pre-cancerous change in the stomach lining).

Peptic Ulcer Disease

A long-running cohort of more than 5,400 men found that carriers of cagA-positive H. pylori had higher rates of both stomach and duodenal ulcers than carriers of cagA-negative strains. In Moroccan and Egyptian populations, cagA-positive infection combined with virulent versions of another H. pylori gene called vacA tracked closely with peptic ulcer disease.

If you have a history of recurrent ulcers despite acid-suppressing treatment, finding a cagA-positive strain helps explain why. Strains carrying cagA produce stronger inflammation and disrupt the stomach lining more aggressively than strains without it.

Pre-Cancerous Stomach Changes

A meta-analysis of human studies found that cagA-seropositive carriers were significantly more likely to have gastric pre-cancerous lesions, including atrophic gastritis and intestinal metaplasia, than people without cagA antibodies. An older endoscopic study reported that infection with a cagA-positive strain was associated with a higher risk of developing atrophic gastritis and intestinal metaplasia over time.

These changes are silent until they become severe. They are the steps along the path from healthy stomach lining to invasive cancer, and they can be reversed or stalled if H. pylori is eradicated early.

Cardiovascular Disease

A meta-analysis of human studies found that H. pylori infection was associated with a mildly increased risk of cardiovascular disease, with cagA-positive strains accounting for much of the association. The link is weaker than the cancer association and not strong enough on its own to drive testing decisions, but it is a reminder that a chronic inflammatory infection in the gut does not stay confined to the gut.

Why Some Findings Look Counterintuitive

A meta-analysis of human studies reported that cagA-positive H. pylori is actually about twice as easy to eradicate with standard antibiotic therapy as cagA-negative H. pylori, with an 11 percent higher eradication success rate. This sounds backwards: the more aggressive strain should be harder to kill. The explanation is that cagA-positive strains tend to grow faster and are more metabolically active, which makes them more vulnerable to antibiotics that work best against actively dividing bacteria. So a cagA-positive result is bad news for your long-term cancer risk if untreated, but good news for the odds that a course of eradication therapy will actually clear the infection.

What the Test Result Means

This is a qualitative test, meaning the result is reported as positive or negative rather than as a number. The cagA gene either is or is not present in the H. pylori strain detected in your stool. Different labs may use slightly different methods (typically PCR-based), so the test should be interpreted alongside a confirmed H. pylori result from the same sample.

Compare your results within the same lab over time for the most meaningful trend. A cagA-positive result on its own is not a diagnosis of any disease; it is a risk signal that should prompt eradication therapy and follow-up testing to confirm clearance.

When Results Can Be Misleading

• Recent antibiotics: any antibiotic course in the prior four weeks can suppress H. pylori below the detection limit, producing a false negative for both H. pylori and cagA.
• Proton pump inhibitors: drugs like omeprazole, pantoprazole, and esomeprazole (commonly called PPIs) can also suppress H. pylori detection and should typically be stopped for at least two weeks before testing if your doctor agrees.
• Bismuth-containing products: Pepto-Bismol and similar bismuth medications have antibacterial activity against H. pylori and can produce false negatives if taken in the days before testing.
• Sample handling: stool samples that are not collected, stored, or shipped according to lab instructions can produce inaccurate results, and a borderline negative is worth repeating before assuming you are uninfected.

Tracking Your Result

If your test is negative for H. pylori, repeat testing every few years is reasonable, especially if you have ongoing symptoms or a family history of stomach cancer. Reinfection is uncommon in adults but can happen, and a strain you pick up later in life may differ from one you cleared earlier.

If your test is positive, retest about four to eight weeks after completing eradication therapy to confirm the infection is gone. Use the same lab and method when possible. Tracking serial results matters more than any single reading because it tells you whether treatment actually worked, not just whether you started off infected.

What to Do If You Test Positive

A cagA-positive result should prompt eradication therapy in nearly every case, regardless of whether you have symptoms. The standard regimens include triple therapy (a proton pump inhibitor plus two antibiotics for 10 to 14 days) or bismuth-based quadruple therapy when antibiotic resistance is a concern. Your doctor or a gastroenterologist can match the regimen to local resistance patterns.

Pair the cagA result with a few companion tests to round out the picture. A full H. pylori virulence panel that also reports vacA, babA, and antibiotic resistance markers helps tailor treatment and risk estimates. If you have had ulcer symptoms, unexplained weight loss, anemia, or a strong family history of stomach cancer, an endoscopy with biopsies is worth discussing with a gastroenterologist to check for atrophic gastritis or intestinal metaplasia. After eradication, retest with a stool antigen or breath test rather than serology, because antibodies can stay positive for years even after the infection is gone.